Hepatitis/MASH

The drug was previously approved to treat HCV in adults

http://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf?la=en

The immunogenicity and safety of hepatitis B surface antigen (HBsAg)/CpG 1018 was assessed in patients with diabetes aged 60 to 70 years.

The study evaluated lymphoma characteristics and outcomes in hepatitis C virus-associated B-cell non-Hodgkin lymphoma in African American patients.

Chronic hepatitis B virus (HBV), which affects an estimated 862,000 individuals in the United States, is caused by long-term infection with the virus and can lead to serious liver damage.

Expanded access to direct-acting antiviral drugs are vital to achieve elimination targets set by the World Health Organization for hepatitis C virus infections.

Transplanting organ from patients infected with hepatitis C could greatly expand the number of kidneys available and reduce wait times.

Top news of the day from across the health care landscape.

A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.

Top news of the day from across the health care landscape.

The hepatitis B virus (HBV) is spread through contact with infected blood or bodily fluids, usually passing into a host via damaged skin (eg, lesions, needlesticks) or mucous membranes, such as the eyes or genitalia.

Top news of the day from across the health care landscape.

Receptor-modified T cells successfully controlled chronic hepatitis B virus, showing promise as a potential cure for the disease.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

This drug was previously approved, in 2017, to treat HCV in adults.

Glecaprevir/pibrentasvir (G/P) plus sofosbuvir and ribavirin can potentially treat patients who experienced previous virologic failure following G/P therapy.

HIV infection is associated with higher rates of hepatitis C replication.

An increasing number of patients with decompensated cirrhosis are receiving direct-acting antiviral treatment and attaining sustained virologic response of hepatitis C, however, their long-term outcomes are unclear.

Study finds chronic hepatitis C virus infection should not delay the initiation of an urgent cancer therapy.

Achievable steps could be taken to reach the World Health Organization goal of eliminating hepatitis B and C virus infections as public health threats by 2030.

A novel vaccine to prevent hepatitis C infection has been tested in Baltimore and at two other sites in the United States.

Kaiser Family Foundation analysis examines Medicaid outpatient prescription drug utilization and spending before rebates.

The study was the first to compare patients with hepatitis C treated with direct-acting antiviral drugs and those untreated for long-term risks.

Because pregnancy is one of the few times individuals are in contact with the health system and covered by health insurance, there is a cost-effective opportunity to screen for hepatitis C virus.

Study finds that glecaprevir/pibrentasvir pan-genotypic efficacy for hepatitis C virus is achieved regardless of whether patients are concurrently receiving gastric acid-reducing drugs.

New research supports the use of direct-acting antiviral therapy for all individuals with chronic hepatitis C infection.

Longitudinal study of direct-acting antivirals for hepatitis C virus infection finds that treatment provides clinical benefit beyond virologic response, reducing risk for both all-cause mortality and for liver cancer.

A novel method of inactivating hepatitis C virus in donor lungs could increase transplantations for patients with end stage lung disease.